Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05927090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Outcomes of Aortic Dissection Repair

Study acronym: STAAD
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 31, 2025 to Dec 31, 2026v8
  2. Re-verified, no change to tracked fieldsv7
  3. Study completion date: Dec 31, 2024 to Dec 31, 2025v6 Show 6 more changesShow less
    • Interventions: Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair (Procedure), Extensive Ascending Aorta Replacement… to Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair (Procedure), Extensive Ascending Aorta Replacement…
    • Study description expanded, about 100 words
    • Site details revised
    • Publications: details revised at 9 of 9 entries
    • Study arms: 4 to 6
    • Study title shortened, about 2 words
  4. Phase: Not applicable to Not specified
    • Enrollment target: 1000 to 1200
    • Study completion date: Dec 30, 2024 to Dec 31, 2024
    • Collaborators: 3 to 5
    v5
  5. Phase: Not specified to Not applicable
    • Site details revised
    • Publications: details revised at 9 of 9 entries
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study completion date: Dec 30, 2023 to Dec 30, 2024v3
  2. Collaborators: 2 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Type A aortic dissection (TAAD) is a potentially life-threatening pathology associated with significant risk of mortality and morbidity. In acute forms of type A aortic dissection (TAAD) mortality is 50% by 24 h and 50% of patients die before reaching a specialist center. Rapid diagnosis and subsequent prompt surgical repair remain the primary goal for these patients. In the last decade it has been observed that improvements in diagnostic techniques, initial management and increased clinical awareness have contributed to a substantial increase in the number of patients benefiting from a prompt diagnosis and undergoing surgery.However, survival after surgical repair has not yet reached optimal follow-ups and is burdened by high in-hospital mortality(16-18%)The main approach to acute type B non-complicated aortic dissection (TBAD) has always been to use medicines to control the patient's heart rate and blood pressure. However, recent findings suggest that a large number of patients treated for acute complicated (TBAAD) and non-complicated TBAD experience aortic complications, such as aneurysmal degeneration, at a later stage.
Trial Details
NCT Number NCT05927090
Lead Sponsor Centre Cardiologique du Nord
Collaborators: Henri Mondor University Hospital, Universita degli Studi di Genova, Pitié-Salpêtrière Hospital, Ospedale San Camillo, Rome, Italy, Campus Bio-Medico University
Conditions
(from sponsor)		 Type A Aortic Dissection, Ascending Aortic Dissection, Aortic Diseases, Aortic Arch, Aortic Valve Insufficiency, Aortic Root Dissection, Aortic Root Dilatation, Type B Aortic Dissection
Related terms Aortic Diseases, Aortic Valve Insufficiency, Dissection, Ascending Aorta
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov